Guy Chamberland, M.Sc., Ph.D., CEO and Chief Regulatory Officer of Tetra Bio-Pharma

Portrait

Dr. Guy Chamberland, M.Sc., PhD, Master Herbalist, has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Scientific Officer since October 15, 2018. He held the positions of Interim Chief Executive Officer and Chief Scientific Officer respectively since April 2018 and June 2016. Dr. Chamberland’s extensive experience in both executive and scientific roles establish him as an expert in the biopharmaceutical space. Dr. Chamberland has more than two decades of experience in drug development for the North American pharmaceutical industry with specific expertise in regulatory affairs, and the development and management of clinical research protocols and clinical studies for botanical medicines. He was also a member of the investment committee of the venture capital fund, Fonds Bionvation, for 7 years.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Superieur de Naturopathie du Quebec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture from McGill University, an M.Sc. in Veterinary Anatomy and physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Sabino Di Paola, CA, CPA, Chief Financial Officer

Portrait

Mr. Di Paola has over a decade of experience in audit, finance and accounting as an auditor for PricewaterhouseCoopers and BDO Canada and has been involved with numerous financing and spin-out transactions. His specialization includes accounting for public and private companies as well as for not for profit organizations. Sabino is a Chartered Public Accountant and holds a degree from Concordia University.

Robert Béchard, Executive Vice President, Corporate Development and Licensing

Portrait

Mr. Béchard brings more than 25 years of experience in finance, venture capital, corporate banking and business development experience to his role as Executive Vice President, Corporate Development and Licensing. Prior to joining Tetra, Mr. Béchard was a Senior Member at RBC Lifesciences, delivering top quartile returns for two separate venture capital funds with investments in American Biotech companies. During his 12-year term as a venture capitalist, Mr. Béchard, was involved in numerous investments, served on the Boards of more than 30 life science companies and oversaw the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies including taking several companies public both in Canada and the U.S. Mr. Béchard has also held key operating roles for an R&D management company and a drug delivery company contributing to their growth as well as serving as a consultant to the biopharmaceutical industry providing start-up assistance in areas of fundraising, strategy, and business and corporate development.

Steeve Néron, Chief Operating Officer

Portrait

Mr. Néron has more than three decades of experience in the pharmaceutical industry where challenging the reimbursement landscape factored prominently in his role, with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada. Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market-leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

Melanie Kelly, Ph.D., Chief Scientific Officer

Melanie Kelly is a Professor In Pharmacology and Ophthalmology at Dalhousie University in Halifax with expertise in preclinical and clinical research design, novel drug development, medical cannabis and cannabinoid based drugs.

A respected research professional with a Doctor of Philosophy (PhD) focused on drug discovery and molecular pharmacology, Dr. Kelly has significant research experience in the field of G protein coupled receptors and endocannabinoid/cannabinoid signaling. She is considered to be an expert in the cannabinoid drug development space.

Her primary research expertise is pharmacology, specifically receptors and cell signaling pathways. Her work has examined pathways important to the survival of retinal ganglion cells in experimental models of glaucoma and has made use of gene mutations, to explore signaling pathways involved in retinal progenitor cell growth and development. Dr. Kelly’s current research addresses the pharmacology of the endocannabinoids and lipid signaling in the mammalian eye, with a specific focus on the regulation of intraocular pressure and interactions between glial cells and microvasculature in the regulation of retinal blood flow.

She is a member of the International Cannabis Research Society.

Aurelia De Pauw, Ph.D., Vice-President, Clinical Programs and Medical Affairs

Dr. De Pauw is responsible for clinical operations and relations with the medical community with a view to building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company. She also directs the Company’s public education initiatives to build and increase awareness about the benefits and adverse effects of cannabis-based treatment.

Aurelia holds a master’s degree and PhD in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium. She followed this with a five-year post-doctoral position in the field of stem cell therapy. After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.

Ofer Yifrach-Stav, M.Sc., Vice President, Pharmaceutical Compliance Quality

Portrait

Mr. Ofer Yifrach-Stav has extensive experience in pharmaceutical and medical device industries where he worked with major medical device, pharmaceutical and cosmetic companies in North America, Europe and Asia. During this time, he successfully lead the preparation of companies for Quality Audits by Health Canada, FDA, EU and Israeli Ministry of Health. Over the years he developed expertise in production process validations and other areas of quality assurance. Ofer is responsible for the scale-up activities of our lead products and ensuring our readiness for the submission of NDS/NDA.

Ofer holds a master’s degree in Environmental Engineering, graduated with honours, and a Bachelor’s degree in Biotechnology Engineering from Ben-Gurion University of the Negev, in Israel.